Explore

Trendline Trendline
BeOne Medicines Honored as 'Outstanding Global Oncology Company' for Advancements in Cancer Therapies

BeOne Medicines Honored as 'Outstanding Global Oncology Company' for Advancements in Cancer Therapies

BeOne Medicines Honored as 'Outstanding Global Oncology Company' for Advancements in Cancer Therapies
Rapid Read Rapid Read
Hokkaido University and BostonGene Collaborate to Enhance Precision Oncology in Japan

Hokkaido University and BostonGene Collaborate to Enhance Precision Oncology in Japan

BostonGene, a developer of AI-powered platforms for tumor and immune biology, has expanded its strategic research collaboration with Hokkaido University in Japan. This multi-year initiative aims to advance precision oncology by integrating molecular and immune data to develop personalized cancer therapies. The collaboration involves next-generation sequencing and integrated analysis of DNA, RNA, and immune system profiling across more than 20 cancer types. The goal is to identify patient-specific disease drivers and guide optimal therapeutic decision-making, thereby improving outcomes for cancer patients in Japan.
Trendline Trendline
Anixa Biosciences Reports Positive Survival Data in Ovarian Cancer Trial

Anixa Biosciences Reports Positive Survival Data in Ovarian Cancer Trial

Anixa Biosciences Reports Positive Survival Data in Ovarian Cancer Trial
Rapid Read Rapid Read
City of Hope Researchers Present New Precision Medicine Insights at ASCO 2026

City of Hope Researchers Present New Precision Medicine Insights at ASCO 2026

City of Hope, a leading cancer research and treatment organization in the United States, is set to present 49 abstracts at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The event, taking place in Chicago from May 29 to June 2, will feature new findings on immunotherapy, precision medicine, and emerging treatment strategies for both blood cancers and solid tumors. City of Hope's participation underscores its commitment to advancing cancer care through precise, effective, and personalized treatments. Key presentations include studies on next-generation immunotherapies, biomarkers for predicting treatment responses, and novel therapeutic combinations. The organization's chief physician executive, Marcel van den Brink, emphasized the importance of these contributions in moving cancer care forward.
Trendline Trendline
Ankyra Therapeutics Showcases Anchored Immunotherapy at PEGS Boston 2026

Ankyra Therapeutics Showcases Anchored Immunotherapy at PEGS Boston 2026

Ankyra Therapeutics Showcases Anchored Immunotherapy at PEGS Boston 2026
Trendline Trendline
Daiichi Sankyo Announces Ambitious Five-Year Plan for Oncology Leadership

Daiichi Sankyo Announces Ambitious Five-Year Plan for Oncology Leadership

Daiichi Sankyo Announces Ambitious Five-Year Plan for Oncology Leadership
Trendline Trendline
Lantern Pharma to Announce Q1 2026 Financial Results Amid AI-Driven Oncology Developments

Lantern Pharma to Announce Q1 2026 Financial Results Amid AI-Driven Oncology Developments

Lantern Pharma to Announce Q1 2026 Financial Results Amid AI-Driven Oncology Developments
Rapid Read Rapid Read
Duke University Research Suggests Cholesterol Drug Could Impact Ovarian Cancer Metastasis

Duke University Research Suggests Cholesterol Drug Could Impact Ovarian Cancer Metastasis

Researchers at Duke University School of Medicine have discovered that the fluid accumulation in the abdomen, known as ascites, which is common in advanced ovarian cancer, may protect cancer cells from ferroptosis, a form of cell death. The study, published in Nature Communications, indicates that ascites provides a survival advantage to cancer cells, aiding their spread. The research also suggests that bezafibrate, a cholesterol-lowering drug, could disrupt this protection, potentially making cancer cells more vulnerable to existing treatments. The findings highlight the role of ascites in promoting tumor survival and dissemination within the peritoneal cavity, a frequent site of metastasis in ovarian cancer.
Trendline Trendline
Anixa Biosciences Announces Positive Survival Data from Phase 1 Ovarian Cancer CAR-T Therapy Trial

Anixa Biosciences Announces Positive Survival Data from Phase 1 Ovarian Cancer CAR-T Therapy Trial

Anixa Biosciences Announces Positive Survival Data from Phase 1 Ovarian Cancer CAR-T Therapy Trial
Rapid Read Rapid Read
University of Illinois Chicago Develops Bacteria-Inspired Cancer Therapy Targeting Tumor Energy Production

University of Illinois Chicago Develops Bacteria-Inspired Cancer Therapy Targeting Tumor Energy Production

Researchers at the University of Illinois Chicago have developed a novel cancer therapy that utilizes a strategy inspired by bacteria residing within tumors. This approach targets the energy production mechanisms of cancer cells rather than attacking the cells directly. The therapy involves a lab-made peptide called aurB, derived from a bacterial protein, which disrupts the mitochondria within cancer cells, thereby hindering their energy supply. In prostate cancer models, the therapy showed significant results, especially when combined with radiation, a standard treatment. The findings, published in Signal Transduction and Targeted Therapy, highlight the potential of targeting mitochondria, the cell's energy factories, as an effective cancer treatment strategy.
Rapid Read Rapid Read
Cleveland Clinic's Innovative Treatment Offers Hope for Terminal Cancer Patient

Cleveland Clinic's Innovative Treatment Offers Hope for Terminal Cancer Patient

Maralee Lellio, diagnosed with Stage IV breast cancer that metastasized to her brain, has experienced a remarkable turnaround in her prognosis thanks to a cutting-edge treatment at the Cleveland Clinic. Initially given a dire prognosis, Lellio's condition improved significantly after being treated with a PARP inhibitor, a medication effective for cancers with genetic mutations like her BRCA-1 positive cancer. Under the care of Dr. Halle Moore, Lellio's brain tumor shrank significantly, and she remained free of active cancer for two years. This treatment has allowed her to pursue her dream of expanding her family, culminating in the birth of her second daughter in July 2024.
Rapid Read Rapid Read
CAR T-Cell Therapy: A Promising Advancement in Cancer Treatment

CAR T-Cell Therapy: A Promising Advancement in Cancer Treatment

CAR T-cell therapy, an innovative cancer treatment, is gaining attention for its potential to enhance the body's immune system to fight cancer. This therapy involves genetically engineering a patient's T-cells to target specific cancer proteins, offering a more precise treatment compared to traditional chemotherapy. The therapy has shown significant success in treating blood cancers, with the potential to prevent relapse by maintaining a protective effect. Researchers are now exploring its application for solid tumors, which present more challenges due to their complex structure. The therapy's development is seen as a major advancement in cancer treatment, with ongoing research aimed at improving its efficacy and reducing costs.